Drugs, diabetes and pharmacogenomics: The road to personalized therapy

Pharmacogenomics

Volumn 12, Issue 5, 2011, Pages 699-701

  Watanabe, Richard M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

developmental delay and epilepsy syndrome; genome wide association; Maturity Onset Diabetes of the Young; neonatal diabetes; phenotyping; sulfonylurea; thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLITAZONE DERIVATIVE; GLUCOKINASE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SULFONYLUREA;

DRUG RESPONSE; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MATURITY ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; REVIEW;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 79957665526     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.29     Document Type: Review

References (20)

1. Meyer UA: Pharmacogenetics -fve decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5(9), 669-676 (2004). (Pubitemid 39150124)
2. Venkatesh T V, Harlow HB: Integromics: challenges in data integration. Genome Biol. 173(8), REPORTS4027 (2002).
3. Byrne MM, Sturis J, Clement Ket al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J. Clin. Invest. 93(3), 1120-1130 (1994). (Pubitemid 24087166)
4. Pearson ER, Flechtner I, Njolstad PRet al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6:2 mutations. N. Engl. J. Med. 3355(5), 467-477 (2006). (Pubitemid 44162274)
5. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ: Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 49(11), 2559-2563 (2006).
6. Stanik J, Gasperikova D, Paskova Met al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J. Clin. Endocrinol. Metab. 92(4), 1276-1282 (2007). (Pubitemid 46556398)
7. Slingerland AS, Hurkx W, Noordam Ket al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet. Med. 25(3), 277-281 (2008). (Pubitemid 351322710)
8. Pearson ER: Pharmacogenetics in diabetes: Curr. Diab. Rep. 9(2), 172-181 (2009).
9. Distefano JK, Watanabe RM: Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals (Basel) 13(8), 2610-2646 (2010).
10. Nelson MR, Bacanu SA, Mosteller Met al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 9(1), 23-33 (2009).
11. Wolford JK, Yeatts KA, Dhanjal SKet al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54(11), 3319-3325 (2005). (Pubitemid 43334389)
12. Buchanan TA, Xiang AH, Peters RKet al. Preservation of pancreatic b-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51, 2796-2803 (2002). (Pubitemid 34970933)
13. Xiang AH, Peters RK, Kjos SLet al. Effect of pioglitazone on pancreatic b-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55, 517-522 (2006). (Pubitemid 43343284)
14. Knowler WC, Barrett-Connor E, Fowler SEet al.; Diabetes Prevention Program Research Group: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393-403 (2002). (Pubitemid 34437694)
15. Knowler WC, Hamman RF, Edelstein SL,et al.; The Diabetes Prevention Program Research Group: Prevention of Type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54, 1150-1156 (2005). (Pubitemid 40446330)
16. DREAM Trial Investigators, Gerstein HC, Yusuf Set al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541), 1096-1105 (2006).
17. Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA: Coordinate changes in plasma glucose and pancreatic b-cell function in Latino women at high risk for Type 2 diabetes. Diabetes 55, 1074-1079 (2006). (Pubitemid 44100184)
18. Mason CC, Hanson RL, Knowler WC: Progression to Type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes 56(8), 2054-2061 (2007). (Pubitemid 47195817)
19. Bergman RN, Zaccaro DJ, Watanabe RMet al. Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes 52, 2168-2174 (2003). (Pubitemid 36919813)
20. Watanabe RM: The genetics of insulin resistance: where's Waldo? Curr. Diab. Rep. 10(6), 476-484 (2010).